ArticleInternational journal of endocrinology2021
Recurrence Factors and Characteristic Trends of Papillary Thyroid Cancer over Three Decades.
Article in International journal of endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Chitosan-based nanoparticles as a targeted drug delivery system to treat thyroid cancer: A literature review.Medicine · 2026Review
- Papillary Thyroid Cancer With Cutaneous Metastasis: A Case Report and Literature Review.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- The role of age and antibodies in central regional lymph node metastases of papillary thyroid carcinoma combined with hashimoto's thyroiditis.BMC cancer · 2026Article
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer.Scientific reports · 2026Article
- Organoid modeling identifies EDN1 as a potential oncogenic driver in papillary thyroid carcinoma via modulation of the Hippo-YAP signaling pathway.Journal of endocrinological investigation · 2026Article
- CD31-associated vascular phenotyping using Doppler ultrasound and dual-energy CT for recurrence risk stratification in papillary thyroid cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Laterocervical Lymph Node Metastases in Papillary Thyroid Carcinoma: Predictive Factors for Recurrence and Oncological Outcome.Journal of personalized medicine · 2025Article
- LncRNA HOTAIR promotes cell proliferation and migration in papillary thyroid carcinoma cells by sponging miR-206/c-Met axis.Journal of molecular histology · 2025Article
- The Current Understanding of the Molecular Pathogenesis of Papillary Thyroid Cancer.International journal of molecular sciences · 2025Review
- BRAF regulates circPSD3/miR-526b/RAP2A axis to hinder papillary thyroid carcinoma progression.BMC molecular and cell biology · 2025Article
- Initial Recurrence Risk Stratification of Papillary Thyroid Cancer based on Intratumoral and Peritumoral Dual Energy CT Radiomics.Current medical imaging · 2025Article
- Ablation of Primary and Recurrent Thyroid Cancer: Current and Future Perspectives.Seminars in interventional radiology · 2024Review
- Selenium in cancer management: exploring the therapeutic potential.Frontiers in oncology · 2024Review
- Nomogram to predict the risk of biochemical recurrence and structural recurrence in patients with stage cN1 papillary thyroid carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Selenium and thyroid diseases.Frontiers in endocrinology · 2023Review
- LncRNA HOTAIR impairs the prognosis of papillary thyroid cancer via regulating cellular malignancy and epigenetically suppressing DLX1.Cancer cell international · 2022Article
- Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.Endocrine · 2022Article
- Nomogram model based on preoperative serum thyroglobulin and clinical characteristics of papillary thyroid carcinoma to predict cervical lymph node metastasis.Frontiers in endocrinology · 2022Article
- Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of thyroid cancer is rising worldwide. Although thyroid cancer has a favorable prognosis, up to 20% of patients experienced recurrent disease during the follow-up period. The present study aimed to examine the trend of incidence and factors associated with recurrence and outcomes of papillary thyroid cancer (PTC) in Thai patients over the last 30 years.
methodsWe reviewed the clinical data of all patients with PTC who were treated between 1987 and 2019 at Theptarin Hospital. Clinical characteristics, epidemic trend, factors associated with the persistence/recurrence of the disease, overall disease-specific survival rate, and overall disease-free survival rate were analysed.
resultsA total of 235 patients with PTC who were registered between 1987 and 2019 were reviewed. The mean age was 42.5 ± 14.3 years, with a mean follow-up of 9.5 years. Papillary thyroid microcarcinoma (PTMC) was consistently increased and accounted for 21.4% (50/235) of total cases. The American Thyroid Association (ATA) risk stratification was high in 24% of all PTMCs in the last decade, and 16.0% of these patients experienced local recurrence during the follow-up period. Coexistence with Hashimoto's thyroiditis (HT) was found in one-fifth of the patients with PTC and was correlated with a low recurrence rate (HR: 0.16,
conclusionsThe prognosis of PTC is generally considered favorable. However, approximately one-fourth of patients with PTMC demonstrated more aggressive clinical behavior, particularly in the last decade of the study. Coexistence of HT contributed to a better prognosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.